Results 41 to 50 of about 17,734 (168)

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source

Soft-tissue response to synthetic polymer implants made of cross-linked polyurethane and containing a biologically active substance, albucid or dacarbazine, in animals

Journal of Ophthalmology, 2018
Background: It is an urgent task of the today’s science to search for and introduce biointegrable synthetic materials into medical practice. Purpose: To investigate the soft tissue response to the polymer sample implants made of cross-linked ...
N.A. Galatenko, D.V. Kulyesh, A.P. Maletskyi, O.S. Karpenko   +3 more
doaj   +1 more source

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

, 2013
BACKGROUND: Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when ...
Dummer, R, Spencer, S, Kim, Kevin B, Liszkay, Gabriella, Schadendorf, D, Kim, KB, Cantarini, M, Cantarini, Mireille, Nyakas, M, Arance, A, Lorigan, P, Schadendorf, Dirk, Kim, Kevin B., Spencer, Stuart, Middleton, Mark R., Robert, Caroline, Gutzmer, Ralf, Lorigan, Paul; id_orcid, Robert, C, Dummer, Reinhard, Gutzmer, R, Arance, Ana, Liszkay, G, Middleton, MR, Nyakas, Marta, Lorigan, Paul, Middleton, Mark R   +26 more
core   +1 more source

Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma

Clinical Pharmacology &Therapeutics, EarlyView.
External control (EC) arms using routine data can be used as comparators in clinical trials under certain conditions. The objective of this study was to assess the ability of an EC arm to replicate outcomes of a randomized controlled trial (RCT) arm receiving the same treatment strategy in advanced stage classical Hodgkin lymphoma and serve as ...
Olivia Febvey‐Combes, Cédric Rossi, Behrouz Kassai, Tesla Murairi Mirimo, Loïc Chartier, Fanny Cherblanc, Emeline Cugnod, Hervé Ghesquières, Aurélien Belot   +8 more
wiley   +1 more source

Navigating Evidence Standards: Stakeholder Perspectives on External Controls and Randomization in Cancer Trials

Asia-Pacific Journal of Clinical Oncology, EarlyView.
While historically the ‘gold standard,’ the role of large‐scale RCTs is being increasingly challenged in the contemporary oncology research era. External controls represent an alternate method for generating evidence, though the perspectives of key stakeholders regarding their role in oncology are not well known.
Sarah E. Heynemann, Wendy L. Lipworth, Sue‐Anne McLachlan, Jennifer Philip, Tom John, Ian H. Kerridge   +5 more
wiley   +1 more source

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma

, 2013
"Background: The effect of the addition of fotemustine and\/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 factorial design trial.
Grimaldi A. M., Grimaldi AM, Daponte A, Caraco C, Lastoria S., Simeone E, Aprea P, Daponte A., Maiorino L, Petrillo A, Mozzillo N, Petrillo A., Cossu A., Comella G., Palmieri G, Aprea P., Ascierto P. A., Botti G, Cossu A, SIGNORIELLO, Simona, Caraco C., Massidda B., Ascierto PA, Cavalcanti E, Palmieri G., Simeone E., Botti G., GALLO, Ciro, Lastoria S, Comella G, Mozzillo N., Maiorino L., Gallo C., Cavalcanti E., Massidda B, Signoriello S.   +35 more
core   +1 more source

Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. [PDF]

PLoS ONE, 2014
BACKGROUND: Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice.
Guan Jiang, Rong-Hua Li, Chao Sun, Yan-Qun Liu, Jun-Nian Zheng   +4 more
doaj   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

INCREASED LEVEL OF MIR-204-5P EXPRESSION IN MELANOMA CELLS UNDER THE INFLUENCE OF DACARBAZINE

Сибирский онкологический журнал, 2019
Various types of tissues was analyzed, and the algorithm for summing neutron and photon doses in neutronMiRNA s are involved in the regulation of numerous critical biological processes, including cell proliferation, differentiation, migration and ...
S. N. Lavrentiev, M. B. Aksenenko, A. S. Averchuk, A. V. Komina, N. V. Palkina, T. G. Ruksha   +5 more
doaj   +1 more source

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
Multiple treatments of unresectable advanced or metastatic melanoma have been licensed in the adjuvant setting, causing tremendous interest in developing neoadjuvant strategies for melanoma.
Mingyi Jing, Mingyi Jing, Yi Cai, Jing Shi, Xufan Zhang, Baohua Zhu, Baohua Zhu, Fan Yuan, Fan Yuan, Jie Zhang, Jie Zhang, Min Xiao, Mingling Chen   +12 more
doaj   +1 more source